Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17


A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.

Holen KD, Belani CP, Wilding G, Ramalingam S, Volkman JL, Ramanathan RK, Vasist LS, Bowen CJ, Hodge JP, Dar MM, Ho PT.

Cancer Chemother Pharmacol. 2011 Feb;67(2):447-54. doi: 10.1007/s00280-010-1346-5. Epub 2010 May 12.


Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.

Carol H, Lock R, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA.

Pediatr Blood Cancer. 2009 Dec 15;53(7):1255-63. doi: 10.1002/pbc.22056.


Microtubule dynamics as a target in oncology.

Risinger AL, Giles FJ, Mooberry SL.

Cancer Treat Rev. 2009 May;35(3):255-61. doi: 10.1016/j.ctrv.2008.11.001. Epub 2008 Dec 30. Review.


Microtubule active agents: beyond the taxane frontier.

Morris PG, Fornier MN.

Clin Cancer Res. 2008 Nov 15;14(22):7167-72. doi: 10.1158/1078-0432.CCR-08-0169. Review.


Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.

Beer TM, Goldman B, Synold TW, Ryan CW, Vasist LS, Van Veldhuizen PJ Jr, Dakhil SR, Lara PN Jr, Drelichman A, Hussain MH, Crawford ED.

Clin Genitourin Cancer. 2008 Sep;6(2):103-9. doi: 10.3816/CGC.2008.n.016.


Progress on kinesin spindle protein inhibitors as anti-cancer agents.

Zhang Y, Xu W.

Anticancer Agents Med Chem. 2008 Aug;8(6):698-704. Review.


Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.

Cox CD, Coleman PJ, Breslin MJ, Whitman DB, Garbaccio RM, Fraley ME, Buser CA, Walsh ES, Hamilton K, Schaber MD, Lobell RB, Tao W, Davide JP, Diehl RE, Abrams MT, South VJ, Huber HE, Torrent M, Prueksaritanont T, Li C, Slaughter DE, Mahan E, Fernandez-Metzler C, Yan Y, Kuo LC, Kohl NE, Hartman GD.

J Med Chem. 2008 Jul 24;51(14):4239-52. doi: 10.1021/jm800386y. Epub 2008 Jun 25.


A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.

Blagden SP, Molife LR, Seebaran A, Payne M, Reid AH, Protheroe AS, Vasist LS, Williams DD, Bowen C, Kathman SJ, Hodge JP, Dar MM, de Bono JS, Middleton MR.

Br J Cancer. 2008 Mar 11;98(5):894-9. doi: 10.1038/sj.bjc.6604264. Epub 2008 Mar 4.


A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.

Lee CW, BĂ©langer K, Rao SC, Petrella TM, Tozer RG, Wood L, Savage KJ, Eisenhauer EA, Synold TW, Wainman N, Seymour L.

Invest New Drugs. 2008 Jun;26(3):249-55. Epub 2007 Oct 26.


An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis.

Tao W, South VJ, Diehl RE, Davide JP, Sepp-Lorenzino L, Fraley ME, Arrington KL, Lobell RB.

Mol Cell Biol. 2007 Jan;27(2):689-98. Epub 2006 Nov 13.


Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage.

Tao W, South VJ, Zhang Y, Davide JP, Farrell L, Kohl NE, Sepp-Lorenzino L, Lobell RB.

Cancer Cell. 2005 Jul;8(1):49-59.


Review: tubulin function, action of antitubulin drugs, and new drug development.

Pellegrini F, Budman DR.

Cancer Invest. 2005;23(3):264-73. Review.


Antitumor activity of a kinesin inhibitor.

Sakowicz R, Finer JT, Beraud C, Crompton A, Lewis E, Fritsch A, Lee Y, Mak J, Moody R, Turincio R, Chabala JC, Gonzales P, Roth S, Weitman S, Wood KW.

Cancer Res. 2004 May 1;64(9):3276-80.


Mechanism of taxane neurotoxicity.

Hagiwara H, Sunada Y.

Breast Cancer. 2004;11(1):82-5. Review.


Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5.

Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ.

J Cell Biol. 2000 Sep 4;150(5):975-88.


New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG.

J Natl Cancer Inst. 2000 Feb 2;92(3):205-16.


Accelerated titration designs for phase I clinical trials in oncology.

Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC.

J Natl Cancer Inst. 1997 Aug 6;89(15):1138-47.


Supplemental Content

Support Center